Actio Biosciences Secures $66 Million Series B Financing to Advance Genetics-Driven Pipeline of Small Molecule Therapeutics for Rare and Common Diseases
Financing co-led by Regeneron Ventures and Deerfield Management will support advancement of lead programs, ABS-1230 and ABS-0871 Phase 1 trial initiation expected in second half 2025 for ABS-1230, a KCNT1 inhibitor for the treatment of…